Ionis Pharma Wins FDA Nod For First RNA-Targeted Therapy For Rare Genetic Swelling Disorder

All NewsAugust 21, 2025

FDA approved Ionis’ Dawnzera for hereditary angioedema, showing up to 87% attack reduction and strong results in switch patients.

We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies.

Cookie settings ACCEPT

Manage consent